

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
20 November 2003 (20.11.2003)

PCT

(10) International Publication Number  
WO 03/094774 A1

(51) International Patent Classification?: A61C 8/00, A61F 2/30

(21) International Application Number: PCT/GB03/02039

(22) International Filing Date: 12 May 2003 (12.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 0210786.0 10 May 2002 (10.05.2002) GB

(71) Applicant (for all designated States except US): PLASMA COATINGS LIMITED [GB/GB]; Whitecross Road Industrial Estate, Tideswell, North Derbyshire SK17 8PY (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): ANDERSON, Duncan, M. [GB/GB]; Whitecross Road Industrial Estate, Tideswell, North Derbyshire SK17 8PY (GB).


(74) Agents: WILLIAMS, Paul, Edwin et al.; Ablett & Stebbing, Caparo House, 101-103 Baker Street, London W1U 6FQ (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: A DENTAL OR ORTHOPAEDIC IMPLANT



(57) Abstract: A dental or orthopaedic implant comprises a metal or metal alloy whose surface has been converted at least over part of its area to an oxide film X, the oxide film comprising a calcium phosphate-containing material as a composite component over at least part of its area Y. The metal or metal alloy preferably comprises a Group IIIA or IVA transition metal or alloy containing the same, and more preferably comprises titanium. The metal or metal alloy surface of the implant is preferably oxidised and/or the composite is preferably formed by Plasma Electrolytic Oxidation. The calcium phosphate-containing material preferably comprises an apatite, for example hydroxylapatite, or tricalcium phosphate. In a preferred PEO process, high frequency current pulses of a particular form, and within a particular frequency range, are used, combined with the generation of acoustic vibrations in 20 a sonic frequency range in the electrolyte, the frequency ranges of the current pulses and the acoustic vibrations overlapping.

WO 03/094774 A1



Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

## A DENTAL OR ORTHOPAEDIC IMPLANT

The present invention relates to a dental or orthopaedic implant, and a method for forming the same.

5

Metal and metal alloys, for example titanium and alloys thereof, are conventionally used in the construction of orthopaedic and dental implants. Such implants are used to replace damaged or diseased bone tissue, and are implanted 10 into living bone, for example employing bone cement, or by direct press-fit contact with the host bone.

However, micro-movement between the implant and the host bone can often result in the generation of so-called "grey-mash" 15 around the implant, i.e. debris of cellular tissue containing metal. Implant loosening, which can ultimately result in revision surgery being required, is known to be mediated by metal particles worn away from the implant (see for example Lalor et al, *The Journal of Bone & Joint Surgery*, Volume 73-B, 20 Number 1, April 1991, and Yanming et al, *The Journal of Bone & Joint Surgery*, Volume 83-A, Number 4, April 2001).

An object of the present invention is to seek to alleviate such problems associated with conventional implants.

25

According to the present invention there is provided a dental or orthopaedic implant, the implant comprising a metal or metal alloy whose surface has been converted at least over part of its area to an oxide film, the oxide film comprising 30 a calcium phosphate-containing material as a composite component over at least part of its area.

The oxide film provides a highly wear resistant and bio-inert

- 2 -

surface, whilst the composite oxide/calcium phosphate-containing material area affords both wear resistance and bioactive properties to encourage direct bone attachment. In particular, the oxide film can help prevent wear due to 5 fretting, i.e. unintended motion of the implant. The oxide film can impart properties to the implant surface similar to those of heat-treated tool steel, for example so as to have a hardness on the Rockwell C hardness scale of from 50 to 60, for example 55.

10

Furthermore, since the oxide/calcium phosphate-containing material composite is provided by converting the metal or metal alloy surface, rather than by applying an additional coating thereto, the dimensions of the implant are not 15 significantly altered.

The calcium phosphate-containing material is incorporated to form a composite comprising the metal or metal alloy oxide and the calcium phosphate-containing material. The calcium 20 phosphate-containing material is thus incorporated within the structure of the oxide film, which provides strength and reliability to any areas of contact between the implant and the host bone. Calcium phosphate is a major constituent of human bones, and the calcium phosphate-containing material 25 encourages bone growth around the implant, which is beneficial in assisting the healing process.

The metal or metal alloy is preferably a light metal or metal alloy, for example a Group IIIA or IVA transition metal or 30 alloy containing the same. Examples of suitable metals include titanium, zirconium, and niobium, with titanium and titanium-containing alloys being particularly preferred. Titanium is particularly strong, light, corrosion resistant, and well

- 3 -

tolerated by the human body.

The metal or metal alloy surface of the implant is preferably converted to the oxide by way of Plasma Electrolytic Oxidation 5 (PEO). PEO is known process, in which a coating is formed on a substrate, in this case the implant, by anode-cathode oxidation in an electrolyte (typically, an alkaline electrolyte) using an alternating current (e.g. an alternating current of 50-60Hz). Suitable PEO processes for preparing the 10 implant of the present invention are disclosed, for example, in WO 99/31303 and WO 01/12883. PEO has an advantage over other coating techniques, for example thermal spraying, in that a relatively thin coating may be applied, which is particular suitable for coating implants which have 15 particularly thin or intricate portions, such as wires.

Thus, those embodiments of the implant provided by the present invention in which the oxide film and/or the oxide/calcium phosphate-containing material composite are formed by PEO are 20 particularly suited for applications where geometrically small implants are required, such as wires (e.g. toe or finger fusing wires), or where particularly delicate or complex implant shapes are required (for example, implants having small recesses, threads or holes). PEO enables the oxide film 25 and/or composite to be relatively thin (for example, 8 to 12 8 to 12 $\mu$ m, as discussed above), which should not disrupt the effectiveness of the implant.

The oxide film may have a thickness in the range of 5 to 50 $\mu$ m, 30 preferably 5 to 20 $\mu$ m, more preferably 8 to 12 $\mu$ m.

The calcium phosphate-containing material may comprise an apatite, for example hydroxylapatite. Crystalline

- 4 -

hydroxyapatite has a thin amorphous phase at its surface, which can initiate an osteoconductive response from host bone. Following implantation, the hydroxylapatite may over time eventually be substantially incorporated into living bone.

5

Alternatively, or additionally, the calcium phosphate-containing material may comprise tricalcium phosphate (TCP), for example  $\alpha$ - or  $\beta$ -TCP, or a mixture thereof. As is the case with hydroxylapatite,  $\alpha$ - or  $\beta$ -TCP is also osteoconductive, 10 and can also thus initiate an osteoconductive response from host bone, and may over time eventually be substantially replaced by living bone. The replacement of TCP by living bone over time makes TCP coating particularly advantageous for implants which are to be removed from a patient, such as 15 fusing pins and wires. Implants coated with TCP are more easy to remove from a patient than implants coated with hydroxylapatite.

The calcium phosphate-containing material is preferably 20 incorporated in the oxide film by PEO, discussed above.

At least part of the area of the surface of the implant of the present invention comprises the oxide/calcium phosphate-containing material composite. However, the composite may 25 extend over substantially the entire surface area of the implant.

In preferred embodiments of the implant of the present invention, at least a part of the surface of the implant also 30 comprises silver particles, as an antimicrobial agent. The use of silver particles reduces the need for antibiotics, after implantation of the implant. The silver particles may be applied to the surface of the implant by PEO, discussed above,

- 5 -

in the form of a silver salt present in the electrolyte. Suitable silver salts for this purpose include silver nitrate, silver sulphate, and silver chloride. The silver particles may be applied to the surface of the implant when forming the 5 composite, i.e. the electrolyte used in the PEO process may comprise both the calcium phosphate-containing material, and a silver salt. Alternatively, the silver particles may be applied to the surface of the implant when oxidising the implant surface. The concentration of silver particles in the 10 implant surface should be controlled so as not to render the implant cytotoxic. Accordingly, the composite preferably comprises 5 to 10 mol% of silver, more preferably from 6 to 9 mol%.

15 The surface of the metal or metal alloy implant will typically be polished prior to applying the oxide and calcium phosphate-containing coating. This facilitates removal of implants from a patient. However, portions of the surface of the implant may be rendered macroporous, for example by having a series of 20 surface grooves or channels, by which mechanical union of the surface with bone tissue is facilitated, which in turn provides additional stability and stress transmission of the implant. As referred to above, PEO has particular advantages in coating such macroporous portions of an implant, since it 25 a complete coating can be applied to the implant surface, even within such grooves or channels.

According to the present invention there is also provided a method for forming a dental or orthopaedic implant, the method 30 comprising the steps of:-

subjecting an implant having a metal or metal alloy surface to oxidation, to convert at least part of the surface of the implant into a metal or metal alloy oxide film,

- 6 -

and converting at least a part of the surface of the implant into a composite oxide film, by reacting the at least part of the oxide film with a calcium phosphate-containing material.

5

The surface of the implant is preferably at least partially converted to the oxide film by PEO, discussed above. In addition, the composite oxide film is also preferably formed by PEO. Thus, in the PEO process, the electrolyte conveniently 10 comprises the calcium phosphate-containing material.

A preferred PEO process is available from Keronite Limited, Cambridge, United Kingdom, and involves the use of high frequency current pulses of a particular form, and within a 15 particular frequency range, combined with the generation of acoustic vibrations in a sonic frequency range in the electrolyte, the frequency ranges of the current pulses and the acoustic vibrations overlapping. In this way, ultra-dispersed powders can be introduced into the electrolyte, the 20 acoustic vibrations helping to form a stable hydrosol, to create coatings with specific properties.

Preferably, the method of the present invention is performed in discrete stages. Thus, in a first stage, at least a part 25 of the surface of the implant is oxidised, following which, in a second discrete stage, the composite is formed with the calcium phosphate-containing material. An advantage of this preferred process, is that the composite is formed only to a shallow depth on the surface of the implant (for example, 2 30 to 5 $\mu$ m). As discussed above, antimicrobial silver particles may be included in the implant surface during either or both of the oxidation and composite forming stages of this preferred method.

- 7 -

An example of the present invention will now be described with reference to the accompanying drawing, in which:-

Figures 1A and 1B show side and front views of an implant of 5 the present invention.

As shown in the Figures, the orthopaedic implant 1 is a Femoral Stem. The implant 1 comprises two areas, designated "X" and "Y". Prior to processing, area "X" of the implant 1 10 has a polished surface. In contrast, area "Y" has a macroporous surface, formed by a series of surface grooves, shown as hatched areas in the Figures. The macroporous surface facilitates mechanical union of area "Y" with bone tissue, which in turn provides additional stability and stress 15 transmission of the implant. Area "X" is not required to form a union with the host bone, but will have intimate contact with the bone, whereas area "Y" is intended to form a union with the host bone.

20 Both areas "X" and "Y" have a thin outer oxide film, formed by a PEO treatment. Subsequently, a further PEO treatment is applied to both areas, during which submicron particle size tricalcium phosphate (TCP) is incorporated into the oxide film to form a composite therewith. The TCP preferably forms a 25 component of the electrolyte used during the PEO process. As referred to above, PEO is particularly useful for coating areas of particular surface detail, such as the grooved surface area "Y", since it allows for coating of the inside of the grooves.

30

The metal oxide film provides a highly wear resistant surface. Incorporating the calcium phosphate as part of the PEO manufacturing process enables the formation of a highly wear

- 8 -

resistant yet bone compatible surface for the purposes of bone attachment.

The metal or metal alloy is preferably a light metal or metal 5 alloy, for example a Group IIIA or IVA transition metal or alloy containing the same. Examples of suitable metals include titanium, zirconium, and niobium, with titanium and titanium-containing alloys being particularly preferred. Titanium is particularly strong, light, corrosion resistant, and well 10 tolerated by the human body.

In a method of forming the implant, the implant is immersed in tanks containing suitable electrolyte for forming the respective films at surfaces "X" and "Y". The formation of the 15 composite film is preferably carried out in a tank in which the electrolyte includes TCP, as discussed above. For those preferred methods which comprise two discrete immersion steps, the area of implant surface not being converted in each step can be masked off.

20

The electrolyte preferably also comprises a silver salt, for incorporation of antimicrobial silver particles into the surface film. Suitable silver salts include silver nitrate, silver sulphate, and silver chloride. By incorporating a 25 silver salt in the electrolyte, the silver particles and calcium phosphate-containing material are simultaneously incorporated onto the surface of the implant.

- 9 -

CLAIMS

1. A dental or orthopaedic implant, the implant comprising a metal or metal alloy whose surface has been converted at 5 least over part of its area to an oxide film, the oxide film comprising a calcium phosphate-containing material as a composite component over at least part of its area.
2. An implant according to claim 1 wherein the metal or 10 metal alloy comprises a Group IIIA or IVA transition metal or alloy containing the same.
3. An implant according to claim 2 wherein the metal or metal alloy comprises titanium, zirconium, or niobium.

15

4. An implant according to claim 3 wherein the metal or metal alloy comprises titanium.
5. An implant according to claim 4 wherein the metal or 20 metal alloy surface of the implant is oxidised and/or the composite is formed by Plasma Electrolytic Oxidation.
6. An implant according to any preceding claim wherein the oxide film has a thickness in the range of 8 to 12 $\mu$ m.

25

7. An implant according to any preceding claim wherein the calcium phosphate-containing material comprises tricalcium phosphate.
- 30 8. An implant according to claim 7 wherein the calcium phosphate-containing material comprises  $\alpha$ - or  $\beta$ -TCP, or a mixture thereof.

- 10 -

9. An implant according to any preceding claim wherein the composite extends over substantially the entire surface area of the implant.

5 10. An implant according to any preceding claim wherein at least a part of the surface of the implant comprises silver particles.

11. An implant according to claim 10 wherein the silver 10 particles are applied to the surface of the implant by plasma electrolytic oxidation.

12. An implant according to claim 11 wherein the silver particles are present as a silver salt present in the 15 electrolyte during the Plasma Electrolytic Oxidation process.

13. An implant according to claim 12 wherein the silver salt is selected from one or more of silver nitrate, silver sulphate, and silver chloride.

20

14. An implant according to any one of claims 10 to 13 wherein the silver particles are applied to the surface of the implant when forming the composite

25 15. An implant according to any one of claims 10 to 14 wherein the silver particles are applied to the surface of the implant when oxidising the implant surface.

16. An implant according to any one of claims 10 to 15 30 wherein the composite comprises 6 to 9 mol% of silver.

17. An implant according to any preceding claim wherein at least part of the surface of the implant is macroporous.

- 11 -

18. An implant according to claim 17 wherein the macroporous surface of the implant is formed by grooves or channels.

19. A method for forming a dental or orthopaedic implant, the 5 method comprising the steps of:-

subjecting an implant having a metal or metal alloy surface to oxidation, to convert at least part of the surface of the implant into a metal or metal alloy oxide film,

and converting at least a part of the surface of the 10 implant into a composite oxide film, by reacting the at least part of the oxide film with a calcium phosphate-containing material.

20. A method according to claim 19 wherein the surface of the 15 implant is at least partially converted to the oxide film and/or the composite oxide film is formed by plasma electrolytic oxidation.

21. A method according to claim 19 or 20 wherein the surface 20 of the implant is oxidised in a first stage, following which the composite is formed with the calcium phosphate-containing material in a second stage.

22. A method according to claim 21 which employs high 25 frequency current pulses of a predetermined form, and within a predetermined frequency range, combined with the generation of acoustic vibrations in a sonic frequency range in the electrolyte, the frequency ranges of the current pulses and the acoustic vibrations overlapping.

30

23. A dental or orthopaedic implant wherein at least a part of the surface of the implant comprises silver particles as an antimicrobial agent.

- 12 -

24. Use of tricalcium phosphate as a coating for a dental or orthopaedic implant.

1/1




Figure 1A

Figure 1B

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/GB 03/02039A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61C8/00 A61F2/30

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61C A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 818 572 A (HOSONUMA MASASHI ET AL) 4 April 1989 (1989-04-04) column 2, line 17 -column 6, line 56 ---	1-9, 17-21, 24
X	US 5 478 237 A (ISHIZAWA HITOSHI) 26 December 1995 (1995-12-26) the whole document ---	1-9, 17-21, 24
X	US 4 846 837 A (KRYSMANN WALDEMAR ET AL) 11 July 1989 (1989-07-11) column 1, line 58 -column 2, line 67; claims ---	1-9, 17-20, 24
X	US 6 214 049 B1 (COMFORT CHRISTOPHER J ET AL) 10 April 2001 (2001-04-10) column 8, line 65 -column 10, line 1; claim 16 --- -/-	1-5, 7-9, 17, 19, 21, 24

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
22 September 2003	06/10/2003
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel: (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer  Fouquet, M

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/GB 03/02039

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 252 525 A (CHILD FRANK W) 24 February 1981 (1981-02-24) abstract	23
A	---	10-16
X	US 5 934 287 A (FURUTA ISAO ET AL) 10 August 1999 (1999-08-10) the whole document	1-4,7-9, 17-19, 21,24
A	US 5 782 910 A (DAVIDSON JAMES A) 21 July 1998 (1998-07-21) column 14, line 15-32	10-16,23
	-----	

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No  
PCT/GB 03/02039

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 4818572	A	04-04-1989	JP	1590432 C	30-11-1990
			JP	2014060 B	06-04-1990
			JP	63099868 A	02-05-1988
			JP	1590433 C	30-11-1990
			JP	2014061 B	06-04-1990
			JP	63099869 A	02-05-1988
			CA	1269898 A1	05-06-1990
			DE	3776066 D1	27-02-1992
			EP	0264354 A2	20-04-1988
US 5478237	A	26-12-1995	JP	2661451 B2	08-10-1997
			JP	7031627 A	03-02-1995
US 4846837	A	11-07-1989	DD	246028 A1	27-05-1987
			EP	0232791 A2	19-08-1987
			JP	2578419 B2	05-02-1997
			JP	62204760 A	09-09-1987
US 6214049	B1	10-04-2001	US	6461385 B1	08-10-2002
US 4252525	A	24-02-1981	NONE		
US 5934287	A	10-08-1999	JP	2893253 B2	17-05-1999
			JP	10099348 A	21-04-1998
			JP	3005893 B2	07-02-2000
			JP	10211218 A	11-08-1998
			JP	3026074 B2	27-03-2000
			JP	11019205 A	26-01-1999
			EP	0832619 A1	01-04-1998
			US	2002143404 A1	03-10-2002
			US	2002128723 A1	12-09-2002
US 5782910	A	21-07-1998	US	5477864 A	26-12-1995
			US	5509933 A	23-04-1996
			US	5169597 A	08-12-1992
			AU	5219693 A	16-06-1994
			CA	2110779 A1	08-06-1994
			EP	0601804 A1	15-06-1994
			JP	6233811 A	23-08-1994
			US	5690670 A	25-11-1997
			US	5716400 A	10-02-1998
			US	5676632 A	14-10-1997
			US	5562730 A	08-10-1996
			US	5713947 A	03-02-1998
			US	5685306 A	11-11-1997
			US	5674280 A	07-10-1997
			US	5683442 A	04-11-1997
			US	5573401 A	12-11-1996
			US	5545227 A	13-08-1996
			AT	104865 T	15-05-1994
			AU	644393 B2	09-12-1993
			AU	6827490 A	27-06-1991
			CA	2032875 A1	22-06-1991
			DE	69008507 D1	01-06-1994
			DE	69008507 T2	18-08-1994
			DK	437079 T3	30-05-1994
			EP	0437079 A1	17-07-1991
			ES	2053126 T3	16-07-1994

**INTERNATIONAL SEARCH REPORT****Information on patent family members**

International	Application No
PCT/GB 03/02039	

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5782910	A	JP 3330380 B2	30-09-2002
		JP 6073475 A	15-03-1994
		ZA 9010217 A	30-10-1991